Spikimm
Develops human monoclonal antibodies to prevent severe viral infections in immunocompromised patients, starting
Highlights
- New on EvolcAdded 2026-11-10
About Spikimm
Spikimm develops human monoclonal antibodies against severe viral infections in immunocompromised patients. Its lead asset, SPK004, targets BK virus reactivation in kidney transplant recipients, a condition for which the company states no approved antiviral therapies currently exist.
The team includes a CEO, a Chief Development Officer, a Chief Medical Officer, a CFO and a Chief Scientific Officer, and the board includes a representative of Truffle Capital.
Spikimm is a French SAS founded in 2021 with its headquarters in Paris.
Product: Human monoclonal antibody therapies; lead asset SPK004 targeting BK virus reactivation in kidney transplant recipients.
Jobs at Spikimm
Leadership
- Paul Gineste · Chief Executive OfficerSource: company website
- Vincent Dagommer · Chief Financial OfficerSource: company website
More biotech & pharma companies
Spore.Bio
AI-based, culture-free microbial detection device and consumables for quality control in factories, from pharma and beveragesYoung companyRemote-friendlySqy Therapeutics
Develops antisense oligonucleotide drug candidates for people with genetic diseases, particularly Duchenne muscular dystrophyStanipharm
CDMO services for life-science companies developing and manufacturing pharmaceutical ingredients and nanoformulationsNew on EvolcStem Genomics
Genomic stability and cell identity testing for research and biotech labs working on human stem cellsNew on EvolcStemcell Technologies
Cell culture products, cell isolation tools, and research services for life science scientists worldwideSteminov
Biotech developing WhartSep stem cell therapy for severe pneumonia and a 3D manufacturing platform for MSCs, offered to drug developersNew on Evolc
Website technologies
Tools and platforms detected on this company’s website, grouped by purpose. Dates record when Evolc observed them.
Content delivery
- CloudflareHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Response headerserver
- Response headerserver
- Response headerserver
Content management
- WixHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Frontend frameworks
- ReactMedium confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Page markupsoftware structure signature
- Page markupsoftware structure signature
- Page markupsoftware structure signature
Monitoring
- SentryHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Website detection does not establish a paid subscription or company-wide use. Tools loaded after consent or sign-in may be missed. “No longer observed” does not prove the company stopped using a tool.